SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: mokelumne river who wrote (1220)5/28/2015 6:27:12 PM
From: eico20  Read Replies (1) | Respond to of 2026
 
James, I was thinking the same on Pascoe's presentation, more proficient and more comfortable with the message, I did not here him say they'd acquire more lifestyle drugs, just another indication on FIS., the news is out on France but the reimbursement is not finalized, so is the French article correct or not, 15% to ceratin indications, we'll see.



To: mokelumne river who wrote (1220)5/28/2015 6:30:11 PM
From: eico20  Respond to of 2026
 
Rayva proof of concept results in June sounds good, indeed his story was compelling, I'll be listening to the adcom meeting on Flib. next week.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News